204 related articles for article (PubMed ID: 18948422)
1. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
[TBL] [Abstract][Full Text] [Related]
2. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
3. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
4. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
5. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
[TBL] [Abstract][Full Text] [Related]
6. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
9. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
10. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
Lounis N; Gevers T; Van Den Berg J; Andries K
Antimicrob Agents Chemother; 2008 Oct; 52(10):3568-72. PubMed ID: 18644960
[TBL] [Abstract][Full Text] [Related]
11. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
Daniel N; Lounis N; Ji B; O'Brien RJ; Vernon A; Geiter LJ; Szpytma M; Truffot-Pernot C; Hejblum G; Grosset J
Am J Respir Crit Care Med; 2000 May; 161(5):1572-7. PubMed ID: 10806157
[TBL] [Abstract][Full Text] [Related]
12. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
[TBL] [Abstract][Full Text] [Related]
13. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.
Grosset J; Lounis N; Truffot-Pernot C; O'Brien RJ; Raviglione MC; Ji B
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1436-40. PubMed ID: 9603120
[TBL] [Abstract][Full Text] [Related]
15. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
Miyazaki E; Chaisson RE; Bishai WR
Antimicrob Agents Chemother; 1999 Sep; 43(9):2126-30. PubMed ID: 10471552
[TBL] [Abstract][Full Text] [Related]
16. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
17. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
[TBL] [Abstract][Full Text] [Related]
18. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
19. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
20. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
